ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the transaction, the vice president owned 74,374 shares in the company, valued at approximately $6,271,959.42. This represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Friday, December 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.32, for a total transaction of $32,928.00.
• On Thursday, November 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $87.27, for a total transaction of $34,908.00.

ANI Pharmaceuticals Trading Up 3.3%

NASDAQ:ANIP opened at $85.03 on Thursday. The firm has a 50-day simple moving average of $82.22 and a 200-day simple moving average of $83.55. ANI Pharmaceuticals, Inc. has a one year low of $54.10 and a one year high of $99.50. The firm has a market cap of $1.91 billion, a P/E ratio of 52.17 and a beta of 0.51. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. During the same period last year, the company posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ANIP shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Guggenheim lifted their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. raised their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Truist Financial upped their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $102.14.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ANIP. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. boosted its stake in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. lifted its holdings in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.